Guided by our ability to monitor in vivo growth, regression and relapse of prostate adenocarcinoma in mouse models, we are now well positioned to isolate tumors at specific stages of the disease progression. Considering the well recognized importance of stromal-epithelial interactions in prostate gland development and in prostate cancer, the central theme of this renewal application is formed on our desire to use this advantage of the model to begin to define important mediators of heterotypic cell interactions that may be critical in progression and recurrence of prostate cancer. All results will then be followed in human prostate cancer samples. Our hypothesis is based on the contention that the multiple secretory and inductive factors including bone morphogenetic proteins (BMPs) and BMP-induced activation of stromal cell-derived factor 1 (SDF-1), a novel interplay between prostate cancer cells and prostate cancer-associated fibroblasts (CAFs) that we have identified, serve critical autocrine, paracrine and endocrine functions in the regulation of growth and survival of prostate cancer cells and associated CAFs, in the intravasation and metastasis of the cancer cells, and in the angiogenic phenotype in the growth and progression of prostate cancer. For the recurrent or androgen depletion-independent (ADI) cancer that emerges following regression from androgen deprivation therapy, we hypothesize that additional changes in inductive factors and in the cellular compartments including epigenetically and/or genetically evolved CAFs may be important contributors.
Our first aim i s to elucidate the mechanisms by which BMP induces CAF cells to produce and secrete SDF-1, using cell systems from both mouse and human prostate cancer, and to define the biological effects of BMP-SDF-1 axis in prostate tumor progression. Our goal is to generate a mechanistic understanding by which BMP and SDF-1 mediate the reciprocal interactions between prostate tumor cells and non-tumor cells within the tumor. In the second aim we will characterize the progression of the ADI prostate cancer with respect to changes in the phenotypic distribution in the epithelial compartment, and with respect to potential molecular and functional changes in the mesenchyme, particularly CAFs that may influence the proliferation and progression of ADI cancer cells. Finally, the third aim concerns an exploitation of the study system to determine the origins of the ADI cancer cells. We will define the prostate stem/ progenitor cell subpopulations during prostate cancer progression, and characterize the functions of these subsets in the varied context of the coevolution of CAFs with the progressive changes in the neoplastic epithelial cells. A series of interconnected and parallel studies, using the mouse models, mouse prostate cells, human prostate cells, and clinical specimens is described to obtain mechanistic insight into specific heterotypic cell interactions that contribute to overall prostate cancer progression, metastasis and recurrence.

Public Health Relevance

We have developed mouse models that mimic the progression of human prostate cancer. We now propose to examine the models to understand the mechanisms of cancer growth, metastasis, regression under anti-androgen therapy, and the recurrence of androgen depletion-independent cancer with the goal to identify new targets for prostate cancer therapy. .

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Sathyamoorthy, Neeraja
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Schools of Medicine
Los Angeles
United States
Zip Code
Liang, Mengmeng; Adisetiyo, Helty; Li, Xiuqing et al. (2015) Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLoS One 10:e0131232
Adisetiyo, Helty; Liang, Mengmeng; Liao, Chun-Peng et al. (2014) Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts. J Cell Physiol 229:1170-6
Geary, Lauren A; Nash, Kevin A; Adisetiyo, Helty et al. (2014) CAF-secreted annexin A1 induces prostate cancer cells to gain stem cell-like features. Mol Cancer Res 12:607-21
Adisetiyo, Helty; Liang, Mengmeng; Liao, Chun-Peng et al. (2013) Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. PLoS One 8:e69484
Pham, Linda Kim; Liang, Mengmeng; Adisetiyo, Helty A et al. (2013) Contextual effect of repression of bone morphogenetic protein activity in prostate cancer. Endocr Relat Cancer 20:861-74
Wu, Xinyu; Gong, Shiaoching; Roy-Burman, Pradip et al. (2013) Current mouse and cell models in prostate cancer research. Endocr Relat Cancer 20:R155-70
Mao, Gloria E; Harris, Diane M; Moro, Aune et al. (2012) A joint effect of new Western diet and retinoid X receptor ? prostate-specific knockout with development of high-grade prostatic intraepithelial neoplasia in mice--a preliminary study. Prostate 72:1052-9
Garlick, David S; Li, Jing; Sansoucy, Brian et al. (2012) ?(V)?(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. Am J Transl Res 4:165-74
Ting, Man-Chun; Liao, Chun-Peng; Yan, Chunli et al. (2012) An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice. Dis Model Mech 5:366-74
Goel, Hira Lal; Chang, Cheng; Pursell, Bryan et al. (2012) VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov 2:906-21

Showing the most recent 10 out of 49 publications